# Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

> **NCT01148459** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK Biological's Investigational Malaria Vaccine 257049
- **BIOLOGICAL:** Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);
- **BIOLOGICAL:** Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).

## Key facts

- **NCT ID:** NCT01148459
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-30
- **Primary completion:** 2013-05-24
- **Final completion:** 2013-05-24
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01148459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01148459, "Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01148459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*